Drug development in higher-risk myelodysplastic syndromes.
作者信息
Venugopal Sangeetha, Sekeres Mikkael A
机构信息
Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
出版信息
Blood Cancer J. 2024 Oct 24;14(1):187. doi: 10.1038/s41408-024-01171-y.
Abstract
摘要
相似文献
1
Drug development in higher-risk myelodysplastic syndromes.高危骨髓增生异常综合征的药物研发
Blood Cancer J. 2024 Oct 24;14(1):187. doi: 10.1038/s41408-024-01171-y.
2
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.来自急性髓系白血病、骨髓增生异常综合征和正常骨髓的CD34+细胞表现出不同的凋亡和耐药相关表型。
Clin Cancer Res. 2004 Nov 15;10(22):7599-606. doi: 10.1158/1078-0432.CCR-04-0598.
3
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.芦可替尼治疗低危骨髓增生异常综合征相关贫血患者（PACE-MDS）：一项多中心、开放标签、2 期剂量发现研究和长期扩展研究。
Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.
4
Novel agents for myelodysplastic syndromes.骨髓增生异常综合征的新型药物。
J Oncol Pharm Pract. 2021 Dec;27(8):1982-1992. doi: 10.1177/10781552211037993. Epub 2021 Sep 24.
5
Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.对于原发性骨髓增生异常综合征患者，骨髓纤维化具有预后价值，可用于当前的治疗方法和新的风险分层系统。
Mod Pathol. 2014 May;27(5):681-9. doi: 10.1038/modpathol.2013.187. Epub 2013 Nov 1.
6
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.法国骨髓增生异常综合征的日常实践管理：一项由法国骨髓增生异常综合征研究组进行的为期一周的横断面研究中 907 例患者的数据。
Haematologica. 2010 Jun;95(6):892-9. doi: 10.3324/haematol.2009.014357. Epub 2009 Dec 16.
7
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?骨髓增生异常综合征与自身免疫性疾病：同一枚硬币的两面？
Lancet Haematol. 2022 Jul;9(7):e523-e534. doi: 10.1016/S2352-3026(22)00138-7.
8
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations.高危骨髓增生异常综合征 3 期临床试验的现状：陷阱与建议。
Lancet Haematol. 2023 Jan;10(1):e71-e78. doi: 10.1016/S2352-3026(22)00265-4. Epub 2022 Oct 7.
9
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.在接受促红细胞生成素刺激剂治疗的、输血依赖的、低危骨髓增生异常综合征患者中，luspatercept 对比 epoetin alfa 的疗效和安全性（COMMANDS）：一项 3 期、开放标签、随机对照临床试验的中期分析。
Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10.
10
Infections in myelodysplastic syndromes.骨髓增生异常综合征中的感染。
Haematologica. 2012 Oct;97(10):1459-70. doi: 10.3324/haematol.2012.063420. Epub 2012 Jun 24.
引用本文的文献
1
Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry.65岁及以上与较年轻成人骨髓增生异常综合征患者异基因造血细胞移植后的结局。拉丁美洲登记处的回顾性分析。
Eur J Haematol. 2025 Oct;115(4):349-357. doi: 10.1111/ejh.70001. Epub 2025 Jun 26.
本文引用的文献
1
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。
Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.
2
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.沙妥利单抗联合低甲基化药物治疗未经治疗的高危骨髓增生异常综合征患者（STIMULUS-MDS1）：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5.
3
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.骨髓增生异常综合征：2023 年关于诊断、风险分层和治疗的更新。
Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8.
4
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.Magrolimab 联合阿扎胞苷治疗高危骨髓增生异常综合征患者的 Ib 期研究的最终结果。
J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.
5
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.2023年国际工作组关于高危骨髓增生异常综合征修订反应标准的共识提案。
Blood. 2023 Apr 27;141(17):2047-2061. doi: 10.1182/blood.2022018604.
6
Considerations for Drug Development in Myelodysplastic Syndromes.骨髓增生异常综合征药物研发的考量因素。
Clin Cancer Res. 2023 Jul 14;29(14):2573-2579. doi: 10.1158/1078-0432.CCR-22-3348.
7
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.阿西米单抗治疗至少两种既往系统性治疗失败后的慢性移植物抗宿主病：一项 I/II 期研究结果。
J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Epub 2022 Dec 2.
8
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.培尼达司他联合阿扎胞苷对比阿扎胞苷单药治疗高危骨髓增生异常综合征/慢性粒单核细胞白血病或低比例骨髓原始细胞急性髓系白血病。
Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334.
9
Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes.Eprenetapopt（APR-246）联合阿扎胞苷治疗 -突变骨髓增生异常综合征。
J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15.
10
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.高危骨髓增生异常综合征中国际工作组反应标准的验证：代表 MDS 临床研究联盟的报告。
Cancer Med. 2021 Jan;10(2):447-453. doi: 10.1002/cam4.3608. Epub 2020 Dec 22.
Zotero 插件